Marker Therapeutics, Inc.
MRKR· Nasdaq
MRKRMarker Therapeutics, Inc.
Filed May 12, 2021 · 10-Q · 42 days after period end · 0001104659-21-065131
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Net Income | -$8.78M | -$6.49M | -$5.32M | -$3.20M |
| EPS Diluted | -$0.16 | -$0.14 | -$0.12 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 12, 2021 · 42 d after period end
